Domain Therapeutics NA is a key partner in multiple drug discovery collaborations
On May 2017, a first collaboration with Pfizer aimed at assessing the impact of naturally occurring variants on different signaling pathways engaged by GPCRs. Single nucleotide polymorphisms can deeply impact the signaling pathways downstream of GPCRs and lead to pathophysiological change leading to multiple diseases. Through this collaboration bioSens-All® has correlated the consequence of a single nucleotide leading to a change in amino acid sequence, with some dramatic impact on GPCRs signaling. Such small but determinant mutation leads to creating partial and sometimes complete gain or loss of function on certain pathways. These observations are highly valuable for the discovery and development of personalized medicines and selection of the right subpopulation of patients, considering each person’s unique genetic background.
On September 2020, Domain Therapeutics and Pfizer signed a collaboration agreement to perform a second research collaboration. This second collaboration aims to profile downstream signaling pathways on a larger set of GPCRs potentially involved across multiple therapeutic areas, using Domain’s bioSens-All® platform technology.
On December 2018, Domain Therapeutics and Boehringer Ingelheim signed a multi-target collaboration agreement on orphan G Protein-Coupled Receptors (GPCRs) in Central Nervous System (CNS) related disorders. The collaboration combines the expertise of Domain Therapeutics in the discovery and the delivery of candidates targeting GPCR with Boehringer Ingelheim’s expertise in the discovery and regulatory development of therapeutics on multiple indications. Via DTNA, bioSens-All® enables a comprehensive characterization of small molecule GPCR binders for the screening and characterization of potential lead compounds. In addition, Domain brings on board its extensive network of leading GPCR experts based in Montreal to provide additional knowledge and insight to the discovery phase (Prof Brigitte Kieffer (Douglas Institute – Montreal, Canada, now INSERM, Strasbourg France) and Prof Michel Bouvier (IRIC Institute – Montreal, Canada).